Empirical first-line treatment with tigecycline for febrile episodes following abdominal surgery in cancer patients

International Journal of Antimicrobial Agents

Volumn 36, Issue 5, 2010, Pages 462-466

  Secondo, Giovanni ^a,b   Vassallo, Francesca ^a   Solari, Nicola ^a   Moresco, Luciano ^a   Percivale, Pierluigi ^a   Zappi, Lucia ^a   Cafiero, Ferdinando ^a   De Maria, Andrea ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cancer; Peritonitis; Sepsis; Tigecycline

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM; CLINDAMYCIN; FLUCONAZOLE; METRONIDAZOLE; TIGECYCLINE;

ABDOMINAL SURGERY; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PERITONITIS; BACTERIUM DETECTION; BILIARY TRACT SURGERY; BLOODSTREAM INFECTION; CANCER PATIENT; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROCOCCUS FAECALIS; ENZYME BLOOD LEVEL; ESCHERICHIA COLI; FEMALE; FEVER; GYNECOLOGIC SURGERY; HUMAN; INFECTION COMPLICATION; INFECTION CONTROL; INTESTINE SURGERY; LARGE INTESTINE CANCER; MAJOR SURGERY; MALE; NAUSEA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REOPERATION; SEPSIS; SIDE EFFECT; STOMACH SURGERY; SURGICAL INFECTION; SURGICAL RISK; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT SURGERY; VOMITING;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; NEOPLASMS; PERITONITIS; SEPSIS; STAPHYLOCOCCUS; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 77957655864     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.07.019     Document Type: Article

References (15)

1. Guinan J.L., McGuckin M., Nowell P.C. Management of health-care-associated infections in the oncology patient. Oncology 2003, 17:415-420.
2. Solomkin J.S., Mazuski J.E., Baron E.J., Sawyer R.G., Nathens A.B., Di Piro J.T., et al. Guidelines for selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003, 37:997-1005.
3. Cattan P., Yin D.D., Sarfati E., Lyu R., De Zelicourt M., Fagnani F. Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 2002, 21:787-793.
4. Sturkenboom M.C., Goettsch W.G., Picelli G., in't Veld B., Yin D.D., de Jong R.B., et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol 2005, 60:438-443.
5. Wacha H., Hau T., Dittmer R., Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 1999, 384:24-32.
6. Frampton J.E., Curran M.P. Tigecycline. Drugs 2005, 65:2623-2635. [discussion 2636-7. Erratum in: Drugs 2006;66:448].
7. Furtado G.H., Bergamasco M.D., Menezes F.G., Marques D., Silva A., Perdiz L.B., et al. Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: risk factors and mortality. J Crit Care 2009, 24. 625.e9-625.e14.
8. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
9. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl. 5):S354-S367.
10. Swoboda S., Ober M., Hainer C., Lichtenstern C., Seiler C., Hoppe-Tichy T., et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008, 61:729-733.
11. Chemaly R.F., Hanmod S.S., Jiang Y., Rathod D.B., Mulanovich V., Adachi J.A., et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) 2009, 88:211-220.
12. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents 2009, 34:585-588.
13. Seguin P., Laviolle B., Chanavaz C., Donnio P.Y., Gautier-Lerestif A.L., Campion J.P., et al. Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 2006, 12:980-985.
14. Montravers P., Lepape A., Dubreuil L., Gauzit R., Pean Y., Benchimol D., et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009, 63:785-794.
15. Nicoletti G., Schito G., Fadda G., Boros S., Nicolosi D., Marchese A., et al. Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital settings. J Chemother 2006, 18:589-602. [Erratum in: J Chemother 2007;19:602-3].